This monograph examines why most analytical innovations fail to become clinical diagnostics. It reframes the problem as structural rather than technological.
The core concept is the “crossing”: the transformation from analytical capability to diagnostic system. Success depends on alignment across regulatory approval, clinical evidence, workflow integration, and market infrastructure—not performance alone. The central tension is clear: analytical systems maximise flexibility, while clinical environments demand constraint and standardisation. Most technologies fail because they cannot operate under these conditions.The monograph offers a framework to assess when crossing is possible—and when it should not be attempted.
Published March 2026 · Persodia Research · Field research: Analytica Munich 2026
Content
IVD Industry Monograph Series. 2
Content. 3
I. A Framework for the Crossing Decision. 4
II. The Structural Paradox: . 5
III. Two Markets, One Crossing. 6
IV. The Attractiveness of Diagnostics — and the Decision to Cross. 9
V. The Crossing to Diagnostics Framework. 11
VI. The Capital Commitment — A Position Worth Building. 15
VII. Crossing Regulatory States. 16
VIII. Observations at Analytica 2026 Munich. 19
IX. Structural Evolution of the Diagnostics Industry. 24
X. The Crossing Is Decided Once, but Proved Over Time. 25
XI. The Crossing Completed. 28
Annexes. 31
Analytical Foundations and Author Information. 33
What this monograph examines
Almost every clinical measurement principle used in hospitals today originated in analytical science. The organisations that built the diagnostics industry were not the ones that developed those principles. They were the ones that understood what it takes to deploy them in a clinical setting.
Most analytical technologies never make that crossing — not because they lack performance, but because they are not built for the institutional conditions of clinical use. This monograph examines why the crossing fails so consistently despite clear economic attraction. It is structured around seven conditions across three phases that must be met simultaneously, none sufficient alone. It draws on the analytical framework developed in Inside the Clinical Diagnostics Industry: Constraints Shaping Strategy — Towards Health Intelligence (Oliveira, 2026) and on field observation at Analytica Munich 2026 — covering the structural gap between the two markets, the capital asymmetry of the crossing, regulatory states as strategic positions, and three detailed failure cases alongside the one crossing that succeeded completely.
Who it is written for
Analytical companies assessing or currently attempting the crossing into clinical diagnostics. Diagnostic manufacturers evaluating competitive positioning and installed base dynamics. Investors assessing diagnostics entry. Institutional leaders and researchers engaged with the structural conditions that govern how diagnostic technologies reach clinical practice. And anyone with a serious interest in how the diagnostics industry actually works.
About the series
This is the first publication in the IVD Industry Monograph series — the primary analytical output of Persodia Research. Each monograph examines a single strategic question at the intersection of industry structure, clinical deployment, and market economics, grounded in the book’s framework and in field research at major industry conferences. The series is observational rather than prescriptive, cumulative rather than episodic.
Access
This monograph is available without charge. All material published through the Persodia Research repository is made freely available. The authors retain full copyright. Material may be read, cited, and discussed freely, but may not be reproduced or repurposed without prior written permission.
Access to the full monograph requires a brief declaration of context and purpose — the authors wish to understand who engages with the material and in what context.
Persodia Research — Gated Content
IVD Industry Monograph No. 1
Enter your details below. A secure, single-use link will be sent to your email address — valid for 24 hours.